Advertisement

Oncology / Hematology General

Prostate cancer treatment choice among Black immigrants

Sep 22, 2022

Large-scale analyses of the prostate cancer (PCa) database have discovered a persistent difference between the death rate of Black patients and that of White patients. Additionally, there were variati...

The Role of Gene Variants in Prostate Cancer Progression: Lymphocyte Modulator, Activation, And Adhesion Genes

Sep 21, 2022

The presence of tumor-infiltrating lymphocytes (TILs) lends credence to the theory that prostate cancer (PCa) growth results from the interaction of epithelial cancer cells with the host's immune syst...

In eSCLC, PEA Represents the Most Effective First-Line Systemic Therapy

Sep 21, 2022

A new standard of care for eSCLC is PEA as first-line systemic therapy. There were currently no known predictive biomarkers for pts selection. For a single-center prospective translational study, r...

16P Development of A 3D Lung Cancer Model and Evaluation of Human Antibodies Directed Against Novel Targets

Sep 21, 2022

For a study, researchers sought to research the progression and metastasis of lung cancer; they used in-vitro cell models. These models—which are often 2D cell cultures—are not accurate representa...

In Cellular Models, Palmitoylethanolamide Co-Incubated with Doxorubicin and Trastuzumab Reduced Cardiotoxicity

Sep 21, 2022

N-acyl phosphatidylethanolamine phospholipase D produces palmitoylethanolamide (PEA), an endogenous fatty acid mediator, from membrane phospholipids. It is a brand-new analgesic with anti-inflammatory...

Trastuzumab Improves the Prognosis of HER2-Positive Breast Cancer Patients

Sep 21, 2022

HER2-positive breast cancer patients now have a better prognosis thanks to trastuzumab. However, the drug can also cause HF or left ventricular dysfunction during therapy. The SGLT2i dapagliflozin had...

HCTRL1 Regulates Progression of Hepatocellular Carcinoma Via TTYH3/MK5 Positive Feedback Loop

Sep 21, 2022

For its diagnosis and treatment, hepatocellular carcinoma (HCC), one of the global causes of cancer-related mortality, requires the discovery of new targets. For a study, researchers sought to examine...

ACC Survival Prediction: 5P Application of Machine Learning Model

Sep 21, 2022

Although machine learning has the potential to change cancer treatment completely, it is not yet being used to treat uncommon tumors like ACC. ACC has a poor prognosis and requires efficient treatment...

4P Immune Checkpoint Inhibitors in ACC

Sep 21, 2022

Adrenocortical carcinoma (ACC) is cancer that is uncommon, severe, and has few available treatments. The way many cancers are treated has been transformed by the use of immune checkpoint inhibitors (I...

Metastatic ACC: 3P Beyond First-line Therapy

Sep 21, 2022

Beyond first-line chemotherapy, there were few effective treatments for the uncommon and aggressive tumor known as metastatic adrenal cortical cancer (ACC). Unfortunately, 2nd line chemotherapy, which...

2MO EO2401 Therapeutic Vaccine for ACC and MPP Patients

Sep 21, 2022

EO was created to stimulate memory T cells that cross-react with antigens linked with tumor associated antigens (TAAs). The HLA-A2 restricted peptides (IL13Rα2, BIRC5, and FOXM1) mimicked by TAAs and...

Cabozantinib for Advanced ACC: 1MO An Open-label

Sep 21, 2022

Adrenocortical carcinoma (ACC) is an uncommon kind of endocrine cancer with few available therapies. For a study, researchers sought to examine carbozantinib's function in ACC treatment. The phase ...

MM Patients: Single-agent anti-PD-1 or Combined Ipilimumab

Sep 21, 2022

An uncommon form of melanoma with a dismal prognosis, mucosal melanoma (MM) has a unique biology. There are few studies on the effectiveness of immune checkpoint inhibitors (ICIs). For a study, resear...

Pimitespib in Advanced GIST Patients (CHAPTER-GIST-301)

Sep 21, 2022

It is not good news when gastrointestinal stromal tumors (GIST) are progressed and are resistant to tyrosine kinase inhibitors (TKIs). In advanced GIST that was resistant to conventional TKIs, researc...

Decipher GC Validation in Patients Receiving SRT Without Hormone Therapy after Radical Prostatectomy

Sep 21, 2022

The Decipher genomic classifier (GC) has demonstrated the ability to predict prostate cancer outcomes independently. Researchers sought to verify the GC in a randomized phase III trial of dose-escalat...

WGTA Enhances Precision Cancer Treatment Options

Sep 21, 2022

Precision genomic medicine is now being delivered to cancer clinics thanks to recent developments. While the bulk of methods focused on profiling panels of chosen genes or hotspot areas, whole-genome ...

Pembrolizumab in MSI-H or Mismatch Repair Deficient Cancers

Sep 21, 2022

In phase II multicohort KEYNOTE-158 research, pembrolizumab showed persistent anticancer efficacy in 233 patients with previously treated advanced solid tumors that had mismatch repair deficient (dMMR...

As A Lymphodepletion Therapy Prior to Tisagenlecleucel, Bendamustine Is Safe and Effective

Sep 20, 2022

B-cell non-Hodgkin lymphomas that have relapsed or become resistant to treatment are often treated using anti-CD19 chimeric antigen receptor T-cell immunotherapy (CAR-T); nonetheless, many patients do...

Acetaminophen and Immunotherapy Effectiveness in Cancer Patients

Sep 20, 2022

Use of acetaminophen (APAP) has been linked to weakened immunological responses to vaccinations. For a study, researchers  evaluated the effect of APAP on the effectiveness of immunotherapy in cancer...

Immunotherapy for Non-Small-Cell Lung Cancer with Unresectable Stage III

Sep 20, 2022

Concurrent chemoradiotherapy (CCRT) and adjuvant durvalumab are the recommended treatments for people with stage III non-small-cell lung cancer (NSCLC). However, despite the increased chance of surviv...